Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 28;20(32):11199-209.
doi: 10.3748/wjg.v20.i32.11199.

MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer

Marion Gayral  1 , Sébastien Jo  1 , Naima Hanoun  1 , Alix Vignolle-Vidoni  1 , Hubert Lulka  1 , Yannick Delpu  1 , Aline Meulle  1 , Marlène Dufresne  1 , Marine Humeau  1 , Maël Chalret du Rieu  1 , Barbara Bournet  1 , Janick Sèlves  1 , Rosine Guimbaud  1 , Nicolas Carrère  1 , Louis Buscail  1 , Jérôme Torrisani  1 , Pierre Cordelier  1
Affiliations
Review

MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer

Marion Gayral et al. World J Gastroenterol. .

Abstract

Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma (PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.

Keywords: Biomarkers; MicroRNAs; Pancreatic cancer; Precancerous lesions; Therapeutic targets.

PubMed Disclaimer

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435–444. - PubMed
    1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806. - PMC - PubMed
    1. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–1117. - PMC - PubMed
    1. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109–1113. - PMC - PubMed

MeSH terms

LinkOut - more resources